Most of the federal contracts with companies involved in the crash program to make COVID-19 vaccines haven't been made public. The lack of disclosure raises questions about accountability.
A panel of doctor and scientists raised questions about the expedited regulatory path the Food and Drug Administration is considering for COVID-19 vaccines.
Here's irony: tobacco plants may be key in preventing COVID-19. Two companies are using the plants to produce proteins for a vaccine. One candidate vaccine is already in a clinical trial.
The move is a reversal of Facebook's longstanding reluctance to block problematic content. Critics say public health misinformation has flourished on the social network.
The requirements laid out by the Food and Drug Administration in advice for drugmakers underscore why it's unlikely a vaccine could clear the agency before Election Day.
Volunteers getting the shot help determine if a candidate vaccine works. But what with social distancing and masks, scientists must discern if it's the shot or these other measures preventing illness.
"We've got to take a deep breath," says one health official about the rapid timeline pushed by the CDC. "It is very clear that we need to lean forward to prepare to deliver the vaccine."
New vaccines usually take years to get the approval of the Food and Drug Administration. But the Trump administration suggests the FDA may greenlight a coronavirus vaccine by the end of the year.
The World Health Organization's Tedros Adhanom Ghebreyesus says he fears that without global cooperation ensuring equal access to COVID-19 vaccines, some countries could resort to hoarding.
The presumptive Democratic nominee now leads President Trump by 11 points. And more people are worried about the coronavirus, but 35% still say they won't get vaccinated when one's available.
Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower.
Adjuvants play a crucial role in many vaccines' effectiveness. Some scientists say there needs to be more research into developing a wider variety of adjuvants because of how important they are.
Two new human studies back earlier hints that vaccines designed to prevent respiratory infections might also provide some protection against Alzheimer's disease.
It warned of the first drop in 28 years for vaccinations against diptheria, tetanus and pertussis — a marker for immunization coverage — based on preliminary data from the first four months of 2020.
As Operation Warp Speed pushes to develop a COVID-19 vaccine in record time, the number of candidates is being narrowed. The factors guiding the decisions about which projects to fund is unclear.
When he was 9 years old, Salk was inoculated by the polio vaccine developed by his father, Dr. Jonas Salk. Today, he is an optimistic about a COVID-19 vaccine but offers a warning.
Experts say the Communist Party sees more at stake than public health. One of the biggest concerns is the economy. China is also looking to defuse criticism over its early handling of the outbreak.
Cambridge, Mass.-based Moderna, Inc., is reporting preliminary data suggesting its COVID-19 vaccine is safe, and appears to be triggering an immune response in test subjects.
The vaccine, developed in a partnership between the pharmaceutical giant and a German biotech company, began trials on Monday with 360 volunteer subjects.
